[Successful treatment of diabetic gustatory hyperhidrosis with topical glycopyrrolate]. 2011

Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
Farmakologisk Institut, Aarhus Universitet, 8000 Aarhus C, Denmark.

Gustatory hyperhidrosis is a condition characterised by excessive craniofacial sweating in relation to food intake and is associated with diabetic neuropathy. The existing guidelines for treatment of this condition include antiperspirants, oral anticholinergic treatment, ionophoresis, botulinum toxin injections and endothoracic surgery. In this case a patient with diabetes suffering from gustatory hyperhidrosis was treated successfully with topical glycopyrrolate, an anticholinergic agent applied directly on the affected area.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005145 Face The anterior portion of the head that includes the skin, muscles, and structures of the forehead, eyes, nose, mouth, cheeks, and jaw. Faces
D006024 Glycopyrrolate A muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics. Glycopyrronium,Glycopyrronium Bromide,NVA 237,NVA-237,NVA237,Pyrrolidinium, 3-((cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, bromide,Bromide, Glycopyrronium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D013547 Sweating, Gustatory An autonomic disorder characterized by excessive sweating of the forehead, upper lip, perioral region, or sternum subsequent to gustatory stimuli. The auriculotemporal syndrome features facial flushing or sweating limited to the distribution of the auriculotemporal nerve and may develop after trauma to the parotid gland, in association with PAROTID NEOPLASMS, or following their surgical removal. (From Ann Neurol 1997 Dec;42(6):973-5) Auriculotemporal Syndrome,Baillarger Syndrome,Frey Syndrome,Hyperhidrosis, Gustatory,Auriculotemporal Nerve Syndrome,Frey's Syndrome,Gustatory Sweating,Salivosudoriparous Syndrome,von Frey Syndrome,von Frey's Syndrome,Gustatory Hyperhidroses,Gustatory Hyperhidrosis,Hyperhidroses, Gustatory,Salivosudoriparous Syndromes,Syndrome, Auriculotemporal,Syndrome, Baillarger,Syndrome, Frey,Syndrome, Frey's,Syndrome, Salivosudoriparous,Syndrome, von Frey,Syndrome, von Frey's,Syndromes, Salivosudoriparous,von Freys Syndrome
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018727 Muscarinic Antagonists Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. Antimuscarinic,Antimuscarinic Agent,Antimuscarinic Agents,Cholinergic Muscarinic Antagonist,Muscarinic Antagonist,Antimuscarinics,Cholinergic Muscarinic Antagonists,Agent, Antimuscarinic,Agents, Antimuscarinic,Antagonist, Cholinergic Muscarinic,Antagonist, Muscarinic,Antagonists, Cholinergic Muscarinic,Antagonists, Muscarinic,Muscarinic Antagonist, Cholinergic,Muscarinic Antagonists, Cholinergic

Related Publications

Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
August 2003, Yonsei medical journal,
Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
December 2021, JAAD case reports,
Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
May 1996, Diabetic medicine : a journal of the British Diabetic Association,
Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
January 2010, Dermatologic therapy,
Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
August 2013, The British journal of dermatology,
Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
December 2016, Journal of the European Academy of Dermatology and Venereology : JEADV,
Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
June 2008, Medicina clinica,
Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
December 2021, Journal of drugs in dermatology : JDD,
Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
May 2008, The British journal of dermatology,
Ninna Sønderby Lund, and Trine Maxel, and Jørgen Rungby
July 2002, Southern medical journal,
Copied contents to your clipboard!